Who Pays My Doctor?

Healthcare provider profile · identity verified

Alexandra Kerner Golant, M.D.

Allopathic & Osteopathic Physicians|Dermatology · NEW YORK, NY · NPI 1831498039

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Alexandra Kerner Golant, M.D. received $930,548.73 in general payments during 2025 across 737 reported records.

GENZYME CORPORATION accounted for 20.8% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 24 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Zoryve.

Arcutis Biotherapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Zoryve as an associated drug or biological on 56906 records involving 10745 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Zoryve by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$930,548.73

737 reported records · 21 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
GENZYME CORPORATION Unresolved — no canonical attribution shown $193,047.4720.8%762025
ABBVIE INC. Unresolved — no canonical attribution shown $127,038.0113.7%812025
Regeneron Healthcare Solutions, Inc. Unresolved — no canonical attribution shown $119,223.4612.8%762025
Arcutis Biotherapeutics, Inc. Unresolved — no canonical attribution shown $114,256.4512.3%1002025
Lilly USA, LLC Unresolved — no canonical attribution shown $106,161.1211.4%712025
Galderma Laboratories, L.P. Unresolved — no canonical attribution shown $90,630.449.7%812025
PFIZER INC. Unresolved — no canonical attribution shown $58,460.246.3%282025
Organon LLC Unresolved — no canonical attribution shown $46,267.025.0%322025
Incyte Corporation Unresolved — no canonical attribution shown $43,021.104.6%752025
LEO Pharma Inc. Unresolved — no canonical attribution shown $17,785.991.9%432025
Eli Lilly and Company Unresolved — no canonical attribution shown $8,713.560.9%62025
Takeda Pharmaceuticals U.S.A., Inc. Unresolved — no canonical attribution shown $4,389.000.5%12025
Janssen Biotech, Inc. Unresolved — no canonical attribution shown $546.340.1%212025
E.R. Squibb & Sons, L.L.C. Unresolved — no canonical attribution shown $393.600.0%92025
UCB, Inc. Unresolved — no canonical attribution shown $187.820.0%142025
Botanix SB Inc Unresolved — no canonical attribution shown $187.680.0%112025
Ortho Dermatologics, a division of Bausch Health US, LLC Unresolved — no canonical attribution shown $81.210.0%42025
Amgen Inc. Unresolved — no canonical attribution shown $66.500.0%32025
Novartis Pharmaceuticals Corporation Unresolved — no canonical attribution shown $52.360.0%32025
LNHC, Inc Unresolved — no canonical attribution shown $21.070.0%12025
Almirall LLC Unresolved — no canonical attribution shown $18.290.0%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program$536,341.88119
Consulting Fee$259,747.0771
Travel and Lodging$78,795.63139
Honoraria$42,400.0010
Food and Beverage$13,264.15398

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
DUPIXENT
Normalized: dupixent		 Biological GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. $243,691.87 131 2025
Source payment records
RINVOQ
Normalized: rinvoq		 Biological ABBVIE INC. $124,271.16 71 2025
Source payment records
Zoryve
Normalized: zoryve		 Drug Arcutis Biotherapeutics, Inc. $114,256.45 100 2025
Source payment records
EBGLYSS
Normalized: ebglyss		 Drug Eli Lilly and Company, Lilly USA, LLC $96,767.48 64 2025
Source payment records
NEMLUVIO
Normalized: nemluvio		 Drug Galderma Laboratories, L.P. $90,426.87 68 2025
Source payment records
VTAMA
Normalized: vtama		 Drug Organon LLC $46,102.52 24 2025
Source payment records
CIBINQO
Normalized: cibinqo		 Drug PFIZER INC. $46,055.49 20 2025
Source payment records
OPZELURA
Normalized: opzelura		 Drug Incyte Corporation $39,916.52 72 2025
Source payment records
ANZUPGO
Normalized: anzupgo		 Drug LEO Pharma Inc. $13,978.84 25 2025
Source payment records
LITFULO
Normalized: litfulo		 Drug PFIZER INC. $12,302.81 8 2025
Source payment records
ADBRY
Normalized: adbry		 Biological LEO Pharma Inc. $3,782.75 18 2025
Source payment records
SKYRIZI
Normalized: skyrizi		 Biological ABBVIE INC. $1,966.85 9 2025
Source payment records
TREMFYA
Normalized: tremfya		 Drug Janssen Biotech, Inc. $546.34 21 2025
Source payment records
TALTZ
Normalized: taltz		 Drug Lilly USA, LLC $304.87 11 2025
Source payment records
AKLIEF
Normalized: aklief		 Drug Galderma Laboratories, L.P. $203.57 13 2025
Source payment records
Bimzelx
Normalized: bimzelx		 Biological UCB, Inc. $187.82 14 2025
Source payment records
SOFDRA
Normalized: sofdra		 Drug Botanix SB Inc $187.68 11 2025
Source payment records
Sotyktu
Normalized: sotyktu		 Drug E.R. Squibb & Sons, L.L.C. $131.33 8 2025
Source payment records
Cabtreo
Normalized: cabtreo		 Drug Ortho Dermatologics, a division of Bausch Health US, LLC $81.21 4 2025
Source payment records
  • 2025-02-19 · Ortho Dermatologics, a division of Bausch Health US, LLC · $22.04 · Open Payments source
  • 2025-08-11 · Ortho Dermatologics, a division of Bausch Health US, LLC · $24.11 · Open Payments source
  • 2025-10-13 · Ortho Dermatologics, a division of Bausch Health US, LLC · $20.42 · Open Payments source
  • 2025-11-24 · Ortho Dermatologics, a division of Bausch Health US, LLC · $14.64 · Open Payments source
OTEZLA
Normalized: otezla		 Drug Amgen Inc. $66.50 3 2025
Source payment records
COSENTYX
Normalized: cosentyx		 Drug Novartis Pharmaceuticals Corporation $52.36 3 2025
Source payment records
SPEVIGO
Normalized: spevigo		 Biological LEO Pharma Inc. $30.70 1 2025
Source payment records
ZELSUVMI
Normalized: zelsuvmi		 Drug LNHC, Inc $21.07 1 2025
Source payment records
Klisyri
Normalized: klisyri		 Drug Almirall LLC $18.29 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments productPayment yearPart D brandPart D yearClaimsMatch methodSource
Zoryve
zoryve		 2025 Zoryve 2024 12
Beneficiary count suppressed		 exact normalized Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying companyPayment yearDrug reported by same entityOpen Payments evidencePart DClaimsBeneficiaries
Arcutis Biotherapeutics, Inc.
Exact reporting entity; no affiliate inference		 2025 Zoryve
open payments reported associated product		 CMS Open Payments — General Payments
56906 supporting records · 10745 recipient NPIs · example record 1252324094 		Zoryve · 2024
Exact normalized brand match · 1 Part D row		 12 suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
Dupixent SyringeDupilumab89suppressed
TacrolimusTacrolimus6028
Dupixent PenDupilumab52suppressed
Clobetasol PropionateClobetasol Propionate4528
MupirocinMupirocin3630
KetoconazoleKetoconazole3419
Betamethasone DipropionateBetamethasone Dipropionate3321
Triamcinolone AcetonideTriamcinolone Acetonide3326
FluocinonideFluocinonide2921
MinoxidilMinoxidil26suppressed
ValacyclovirValacyclovir Hcl26suppressed
Ammonium LactateAmmonium Lactate2311
CiclopiroxCiclopirox Olamine1814
HydrocortisoneHydrocortisone1612
TretinoinTretinoin14suppressed
CiclopiroxCiclopirox12suppressed
ZoryveRoflumilast12suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $930,548.73 · 737 records GENZYME CORPORATION ADBRY, AKLIEF, ANZUPGO, Bimzelx, CIBINQO, COSENTYX, Cabtreo, DUPIXENT, EBGLYSS, Klisyri, LITFULO, NEMLUVIO, OPZELURA, OTEZLA, RINVOQ, SKYRIZI, SOFDRA, SPEVIGO, Sotyktu, TALTZ, TREMFYA, VTAMA, ZELSUVMI, Zoryve 1 —
2024 — — — — Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error